| Literature DB >> 33431490 |
Mary Carter1, Sarah Chapman2, Margaret C Watson3.
Abstract
OBJECTIVES: Despite widespread availability of evidence-based guidelines to inform rational use of medicines, considerable unwarranted variation exists in prescribing. A greater understanding of key determinants of contemporary prescribing in UK general practice could inform strategies to promote evidence-based prescribing. This study explored (1) current influences on prescribing in general practice and (2) the possibility that general practice-based pharmacists (PBPs) may contribute to greater engagement with evidence-based prescribing.Entities:
Keywords: organisation of health services; primary care; protocols & guidelines; qualitative research
Year: 2021 PMID: 33431490 PMCID: PMC7802664 DOI: 10.1136/bmjopen-2020-041460
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Target recruitment matrix
| General practice prescribers | Key informants | ||
| Gender | Male | Gender | Male |
| Female | Female | ||
| Role | General practitioner | NHS level | Local |
| Practice-based pharmacist Nurse | |||
| Regional | |||
| National | |||
| Years since qualification | ≤10 | Years in current post | ≤2 |
| >2 | |||
| >10 | |||
| Employment | Clinical Commissioning Group | Direct contact with general practice | Yes |
| Practice | No | ||
| NHS England | |||
| Practice size (patient list) | Small (<5000 patients) | ||
| Medium (5000–≤10 000 patients) | |||
| Large (>10 000 patients) | |||
| Practice level of deprivation* | ≤5 | ||
| >5 | |||
*Information from National General Practice Profiles41 (lower numbers indicate more deprivation).
Prescriber and general practice characteristics
| Individual characteristics | General practice characteristics | |||||
| Participant no. | Gender | Employer and work location | Years since registration | Years since qualifying as independent prescriber | Practice list size | Indices of multiple deprivation decile* |
| General practitioners | ||||||
| P10 | F | Practice, England (West) | 20 | 5000–≤10 000 | ≤5 | |
| P12 | M | Practice, England (South West) | 36 | 5000–≤10 000 | >5 | |
| P13 | F | Practice, Scotland | 26 | 5000–≤10 000 | >5† | |
| P14 | F | Practice, England (South West) | 31 | 5000–≤10 000 | >5 | |
| P16 | F | Practice, England (South West) | 26 | >10 000 | >5 | |
| P18 | F | Practice, England (Midlands) | 12 | 5000–≤10 000 | ≤5 | |
| Practice-based pharmacists | ||||||
| P3 | M | Practice, England (South) | >10 | >5 | >10 000 | >5 |
| P9 | M | Group of four practices, England (London) | <10 | ≤5 | <5000 | ≤5 |
| >10 000 | >5 | |||||
| >10 000 | <5 | |||||
| >10 000 | <5 | |||||
| P11 | M | Practice, England (West) | <10 | ≤5 | >10 000 | >5 |
| P22 | M | Practice, England (South) | >10 | ≤5 | >10 000 | ≤5 |
| P29 | F | Practice, England (East) | <10 | ≤5 | >10 000 | >5 |
| P32 | M | Community pharmacy/practice, England (South) | >10 | ≤5 | 5000–≤10 000 | >5 |
| Nurses | ||||||
| P5 | F | Practice, Wales | >10 | >5 | >10 000 | >5† |
| P1 | M | Practice, England (West) | >10 | >5 | >10 000 | >5 |
| P15 | F | Practice, England (West) | >10 | >5 | >10 000 | >5 |
| P19 | F | Practice, England (Midlands) | >10 | >5 | >10 000 | ≤5 |
| P21 | F | Practice, England (South) | >10 | ≤5 | >10 000 | >5 |
P9 worked in four practices; P3 and P21 worked in the same practice.
All PBPs and nurses were independent prescribers.
*Information from National General Practice Profiles41 (lower numbers indicate more deprivation).
†Derived from participant’s depiction of patient population.
Key informant characteristics
| Participant no. | Gender | Age (years) | National Health Service level Local*/regional†/national‡ (England) | Time in post (years) | Direct contact with general practices | Interview or focus group |
| P2 | F | >30–≤50 | Local | ≤2 years | Y | Interview |
| P4 | F | >50 | Regional | >2 | Y | Interview |
| P8 | F | >30–≤50 | Local | ≤2 | Y | Interview |
| P17 | F | >50 | National | >2 | N | Interview |
| P23 | F | >50 | Local and regional | >2 | Y | Interview |
| P24 | M | >50 | Local and regional | >2 | N | Focus group |
| P25 | F | >30–≤50 | Local and regional | >2 | Y | Focus group |
| P26 | M | >30–≤50 | National and regional | >2 | Y | Focus group |
| P27 | M | >50 | Local and regional | >2 | Y | Focus group |
| P28 | F | >50 | National and regional | >2 | Y | Focus group |
| P31 | M | >50 | National and regional | >2 | N | Interview |
*Local: working at individual Clinical Commissioning Group level.
†Regional: working across Clinical Commissioning Groups or regional body.
‡National: representative of/working on national body.
Figure 1Comparison of prescriber and key informant perspectives. CCG, Clinical Commissioning Group; NHS, National Health Service; NICE, National Institute of Health and Care Excellence; PBP, practice-based pharmacist.